Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar...(ers. ITI's CNSProfile(TM) has shown t...),Health

ITI's CNSProfile(TM) has shown that, unlike some atypical antipsychotics, ITI-007 does not exhibit significant potency for a variety of other targets that have been implicated in a range of dose-limiting side effects of antipsychotic drugs. ITI-007 does not interact with muscarinic or histaminergic receptors and has a reduced affinity for adrenergic receptors relative to other antipsychotic drugs and relative to its potency at 5HT2A receptors.

ITI-002 Study Results

ITI-002 was shown to be an orally active and a potent inhibitor of a novel intracellular target and was designed to amplify but not supplant ongoing activity of D1 receptive neurons, primarily in the prefrontal cortex. In behavioral studies, ITI-002 displayed acute and chronic activity as a cognitive enhancing agent in rodent models. ITI-002 has been shown to be safe in all preliminary evaluations and is advancing to pre-clinical development. It is envisioned that activation of D1 activity will improve the cognitive deficits seen in patients with schizophrenia.

About ITI-007

ITI-007 is an orally available compound that combines potent 5HT2A receptor antagonism with cell-type-specific modulation of phosphoprotein pathways downstream of dopamine receptors. As a dopamine receptor phosphoprotein modulator (DPPM), ITI-007 has dual properties; it acts as a post-synaptic antagonist and as a pre-synaptic partial agonist. The combination of ITI-007's high-potency blockade of 5HT2A receptors and unique dopamine receptor activity will make it possible for the first time to select a clinical dose capable of saturating 5HT2A receptors while permitting the 'dialing in' of an optimal amount of dopamine receptor modulation by simple dose adjustments using a single drug. The ability to optimize the level of dopamine receptor modulation holds promise for the reduction of psychotic symptoms without incurring high levels of dopamine antagonism that cause motor disturbances and other de
'/>"/>